Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report

Laura M. Kulik; Mary F. Mulcahy; Russell D. Hunter; Albert A. Nemcek; Michael M. Abecassis; Riad Salem

doi:10.1002/lt.20514

Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report

Laura M. Kulik, Mary F. Mulcahy, Russell D. Hunter, Albert A. Nemcek, Michael M. Abecassis, Riad Salem

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

Original language	English (US)
Pages (from-to)	1127-1131
Number of pages	5
Journal	Liver Transplantation
Volume	11
Issue number	9
DOIs	https://doi.org/10.1002/lt.20514
State	Published - Sep 2005
Externally published	Yes

ASJC Scopus subject areas

Surgery
Hepatology
Transplantation

Access to Document

10.1002/lt.20514

Cite this

@article{9e0b3f69cd964bb7a88f96cae4719e77,

title = "Use of Yttrium-90 microspheres (TheraSphere{\textregistered}) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report",

abstract = "Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.",

author = "Kulik, {Laura M.} and Mulcahy, {Mary F.} and Hunter, {Russell D.} and Nemcek, {Albert A.} and Abecassis, {Michael M.} and Riad Salem",

year = "2005",

month = sep,

doi = "10.1002/lt.20514",

language = "English (US)",

volume = "11",

pages = "1127--1131",

journal = "Liver Transplantation",

issn = "1527-6465",

publisher = "John Wiley and Sons Ltd",

number = "9",

}

TY - JOUR

T1 - Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation

T2 - A case report

AU - Kulik, Laura M.

AU - Mulcahy, Mary F.

AU - Hunter, Russell D.

AU - Nemcek, Albert A.

AU - Abecassis, Michael M.

AU - Salem, Riad

PY - 2005/9

Y1 - 2005/9

N2 - Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

AB - Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

UR - http://www.scopus.com/inward/record.url?scp=25144441790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144441790&partnerID=8YFLogxK

U2 - 10.1002/lt.20514

DO - 10.1002/lt.20514

M3 - Article

C2 - 16123954

AN - SCOPUS:25144441790

SN - 1527-6465

VL - 11

SP - 1127

EP - 1131

JO - Liver Transplantation

JF - Liver Transplantation

IS - 9

ER -

Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this